Improvement of Insulin Sensitivity by a Novel Drug, BGP-15, in Insulin-resistant Patients: A Proof of Concept Randomized Double-blind Clinical Trial
- 12 February 2009
- journal article
- research article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 41 (05), 374-380
- https://doi.org/10.1055/s-0028-1128142
Abstract
The efficacy and safety of the new drug, BGP-15, were compared with placebo in insulin-resistant patients in a 28-day dose-ranging study. Forty-seven nondiabetic patients with impaired glucose tolerance were randomly assigned to 4 weeks of treatment with 200 or 400 mg of BGP-15 or placebo. Insulin resistance was determined by hyperinsulinemic euglycemic clamp technique and homeostasis model assessment method, and β-cell function was measured by intravenous glucose tolerance test. Each BGP-15 dose significantly increased whole body insulin sensitivity (M-1, p=0.032), total body glucose utilization (M-2, p=0.035), muscle tissue glucose utilization (M-3, p=0.040), and fat-free body mass glucose utilization (M-4, p=0.038) compared to baseline and placebo. No adverse drug effects were observed during treatment. BGP-15 at 200 or 400 mg significantly improved insulin sensitivity in insulin-resistant, nondiabetic patients during treatment compared to placebo and was safe and well-tolerated. This was the first clinical study demonstrating the insulin-sensitizing effect of a molecule, which is considered as a co-inducer of heat shock proteins.Keywords
This publication has 18 references indexed in Scilit:
- Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndromeFertility and Sterility, 2006
- Metformin Increases Insulin Sensitivity and Plasma β-endorphin in Human SubjectsHormone and Metabolic Research, 2006
- Induction of heat shock proteins may combat insulin resistanceMedical Hypotheses, 2006
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005
- Heat shock proteins as emerging therapeutic targetsBritish Journal of Pharmacology, 2005
- Insight into hepatotoxicity: The troglitazone experienceHepatology, 2005
- Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS miceNature Medicine, 2004
- Methods for clinical assessment of insulin sensitivity and β-cell functionBest Practice & Research Clinical Endocrinology & Metabolism, 2003
- Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1Biochemical and Biophysical Research Communications, 2003
- A central role for JNK in obesity and insulin resistanceNature, 2002